Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05275686
Other study ID # IIT-WU-2021-EuPEN
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date April 20, 2022
Est. completion date January 2025

Study information

Verified date March 2024
Source Cedars-Sinai Medical Center
Contact Missael Vasquez
Phone 424-315-2437
Email missael.vasquez@cshs.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Intranasal nasal steroid sprays are the mainstay of treatment for chronic Eustachian tube dysfunction despite having little supportive evidence in the literature. A novel, commercially available nasal spray delivery system is available now for fluticasone that improves its delivery to the nasopharynx. The hypothesis of this study is that fluticasone using the novel spray system is effective for Eustachian tube dysfunction (ETD).


Description:

BACKGROUND AND RATIONALE Eustachian tube dysfunction (ETD) can be a symptom of allergic rhinitis, non-allergic rhinitis, or chronic rhinosinusitis. However, it can also be a separate entity with patients displaying no other symptoms of the previously mentioned diseases. There is currently no FDA- approved medication specifically for eustachian tube dysfunction, but most otolaryngologists, allergists, and primary care physicians employ multiple different over-the-counter and prescription medications for its treatment. Most common are oral and topical antihistamines, nasal steroid sprays, topical and oral decongestants, and oral steroids. Nasal steroid sprays, which are FDA-approved for allergic rhinitis, are most frequently used for chronic ETD despite a lack of large clinical trials to support their use. These sprays do have good safety profiles, are frequently available over-the-counter, and do have good data on their efficacy in rhinitis and sinusitis. Fluticasone nasal spray is available over the counter and is a nasal steroid spray. It is frequently recommended or prescribed for chronic eustachian tube dysfunction. However, its efficacy and the efficacy of all nasal sprays may be limited by the access of previously available sprays into the nasopharynx. The level of evidence for these sprays in chronic ETD is poor overall with only one randomized controlled trial in adults. This study determined no benefit over placebo. In studies determining the deposition of nasal sprays, most of the spray is deposited in the front of the nasal cavity over the inferior turbinates and very little gets into the sinus cavities or nasopharynx. A new exhalational delivery system fluticasone spray (EDS-FLU) has been FDA-approved for patients with chronic rhinosinusitis with polyps. The main difference between this spray and previously available sprays is that it penetrates deeper into the sinuses and also to the nasopharynx, the location of the eustachian tubes. In this system, the user blows out while pumping the spray bottle and his/her breath is the driving force of the spray bottle. Blowing out also elevates the soft palate, seals the nasopharynx, and contains all the spray into the nasal cavity, sinuses, and nasopharynx. In a traditional spray, the soft palate is at resting position, and the spray can pass through the nasal cavity and down into the oropharynx and mouth. This is typically perceived by many users as postnasal drip after the use of nasal sprays. The investigators have previously published a retrospective review of the use of EDS-FLU in patients with at least 1 month of ETD symptoms and found that 79% had improvement more than the minimal clinically important difference. Thirty-six percent of patients normalized with regards to symptoms, and 80% of patients with pre- and post-treatment tympanometry normalized their tympanogram. This study will compare placebo to fluticasone exhalational nasal spray system (Xhance) in a randomized, controlled study.


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Age greater than or equal to 18 years old, <80 years old - Chronic Eustachian tube dysfunction defined as: - Symptoms in one or both ears > 3 months AND - ETDQ-7 score >14.5 AND - Type B, C, or As tympanometry - Female subjects of childbearing potential must have a negative urine pregnancy test at screening and throughout the study duration. Exclusion Criteria: - Age <18 years old - Known history of otologic surgery (excluding myringotomy or myringotomy tubes) - Use of any additional intranasal medication - Tympanic membrane perforation - Adhesive otitis media - Cholesteatoma or significant retraction pocket - Middle ear effusion - Nasopharyngeal tumor - Any history of head and neck cancer - Any history of head and neck irradiation - Any history of temporomandibular disorder or prior surgery to the temporomandibular joint - Any medical condition that the investigator deems inappropriate for enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray
Patients will use two sprays in each nostril twice a day for 6 weeks and additional 6 weeks (open label).
Other:
Placebo Nasal Spray
The Placebo is made of the following ingredients: Purified Water, Microcrystalline Cellulose RC-591, Dextrose, Anhydrous, EDTA Disodium Dihydrate, Benzalkonium Chloride Solution 50%, Polysorbate 80 (Tween 80, HP-LQ-(MH)), Sodium Hydroxide, and Hydrochloric Acid. Patients will use two sprays in each nostril twice a day

Locations

Country Name City State
United States Indiana University Indianapolis Indiana
United States Cedars-Sinai Medical Center Los Angeles California
United States Ochsner Health System New Orleans Louisiana
United States Sacramento Ear, Nose & Throat Sacramento California

Sponsors (4)

Lead Sponsor Collaborator
Cedars-Sinai Medical Center Indiana University, Ochsner Health System, Sacramento Ear, Nose & Throat

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary 7-Item Eustachian Tube Dysfunction Questionnaire (ETDQ-7) Eustachian tube dysfunction symptoms measured by the validated quality of life 7-Item Eustachian Tube Dysfunction Questionnaire (ETDQ-7) at visit 2.
The scale is from 1 (no problem) to 7 (severe problem).
visit 2 (week 6)
Primary 7-Item Eustachian Tube Dysfunction Questionnaire (ETDQ-7) Eustachian tube dysfunction symptoms measured by the validated quality of life 7-Item Eustachian Tube Dysfunction Questionnaire (ETDQ-7) at visit 3.
The scale is from 1 (no problem) to 7 (severe problem).
visit 3 (week 12)
See also
  Status Clinical Trial Phase
Completed NCT04776967 - Effect of Total Compression Time and Rate (Slope) on Incidence of Symptomatic ETD and MEB: A Phase II Prospective Study. N/A
Recruiting NCT04804098 - Effect of Rate (Slope) of Compression on the Incidence of Symptomatic ETD and MEB: a Phase III Prospective Study. N/A
Terminated NCT01974726 - Gas Supply, Demand and Middle Ear Gas Balance -- Diagnosis of Eustachian Tube Dysfunction N/A
Recruiting NCT05600595 - The Evaluation of Eustachian Tube Function and Its Influencing Factors After Snoring Operation in Children
Not yet recruiting NCT05998356 - Long-term Assessment of Balloon Eustachian Tuboplasty for Obstructive Eustachian Tube Disease N/A
Not yet recruiting NCT03322579 - Balloon Dilation of the Eustachian Tube, a Lower Pressure Challenge N/A
Withdrawn NCT03886740 - Tympanostomy Tubes Versus Eustachian Tube Dilation N/A
Completed NCT04809753 - Eustachian Tube Dilation With an Endovascular Balloon N/A
Withdrawn NCT02631187 - Feasibility Study of Balloon Eustachian Tuboplasty (BET) N/A
Completed NCT04902963 - What is the Tympanic Membrane Healing Time After Insertion of a Gelfoam PE Tube? N/A
Completed NCT04136977 - XprESS ET Registry
Completed NCT03197558 - Adult Study to Evaluate Placement of Tympanostomy Tubes In-office (ADEPT) Phase 2
Recruiting NCT05719207 - Efficacy of Balloon Dilation of the Eustachian Tube in Eustachian Tube Dilatory Dysfunction N/A
Completed NCT01251432 - Risk Factors and Potential Causes of Eustachian Tube Dysfunction in Adults N/A
Recruiting NCT05055115 - Ph.D.-Project: Eustachian Tube Dysfunction: Causes, Diagnosis, Treatment, and Prognosis N/A
Recruiting NCT04645511 - Balloon Sinuplasty Efficiency in Maxillary Rhinosinusitis. N/A
Not yet recruiting NCT05222230 - FFP3 Respirators and Ears - Effects on Middle Ear Pressure and Hearing N/A
Completed NCT02667301 - Eustachian Tube Dysfunction Assessment N/A
Not yet recruiting NCT05229380 - Pretympanoplasty Assessment of Patency and Mucociliary Function of Eustachian Tube
Completed NCT03850197 - Tubomanometry and EarPopper Devices for Eustachian Tube Function Testing